Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Moussa, S; Ansari-Shahrezaei, S; Smretschnig, E; Hagen, S; Steindl-Kuscher, K; Krebs, I; Binder, S.
Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization.
Graefes Arch Clin Exp Ophthalmol. 2010; 248(8):1087-1090
Doi: 10.1007/s00417-010-1341-x
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Ansari Shahrezaei Siamak
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To evaluate contrast sensitivity (CS) using Pelli-Robson charts after intravitreal ranibizumab (IVR) (Lucentis, Novartis, Basel, Switzerland) or bevacizumab (IVB) (Avastin, Genentech, South San Francisco, California, USA) in eyes with myopic choroidal neovascularization (mCNV). A retrospective review was performed of 17 consecutive patients treated with IVR (n = 10; 0.5 mg) or IVB (n = 7; 1.25 mg) for mCNV from July, 2006 with follow-ups through September, 2009. Re-treatment was performed at monthly or longer intervals if there was fluorescein leakage in fluorescein angiogram (FAG) and or apparent subretinal fluid in optical coherence tomography (OCT) persisted. CS improved by a mean of one letter at 1 month (n = 17; p = 0.32), four letters at 3 months (n = 17; p = 0.02), four letters at 6 months (n = 15; p = 0.01), five letters at 9 months (n = 14; p = 0.04) and six letters at 12 months (n = 13; p = 0.03). The mean number of IVR/IVB was 1.6/1.6, 2.6/2.3, 3.1/3.2, 4.1/4.2 and 4.5/4.6 at 1 month, 3 months, 6 months, 9 months, and 12 months, respectively. Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiogenesis Inhibitors - administration & dosage
- Antibodies, Monoclonal - administration & dosage
- Antibodies, Monoclonal, Humanized -
- Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology
- Contrast Sensitivity - physiology
- Female -
- Fluorescein Angiography -
- Humans -
- Injections -
- Male -
- Middle Aged -
- Myopia, Degenerative - drug therapy Myopia, Degenerative - physiopathology
- Retreatment -
- Retrospective Studies -
- Tomography, Optical Coherence -
- Treatment Outcome -
- Vascular Endothelial Growth Factor A - antagonists & inhibitors
- Vitreous Body -
- Find related publications in this database (Keywords)
- Bevacizumab
- Myopic choroidal neovascularization
- Pelli-Robson contrast sensitivity
- Ranibizumab